--- title: "MapLight Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295849654.md" datetime: "2026-08-13T21:24:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295849654.md) - [en](https://longbridge.com/en/news/295849654.md) - [zh-HK](https://longbridge.com/zh-HK/news/295849654.md) generator: "portal-rs" --- # MapLight Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -1.32, missing the estimate of USD -1.3146. EBIT: As of FY2026 Q2, the actual value is USD -62.54 M. #### Cash Position As of June 30, 2026, MapLight Therapeutics, Inc.’s cash, cash equivalents, and investments totaled $351.3 million. Unaudiated cash, cash equivalents, and investments were $351 million as of June 30, 2026. Pro forma for $150 million in gross proceeds from a private placement announced in August 2026, the company’s cash position is approximately $501 million. #### Private Placement Financing (PIPE) MapLight Therapeutics, Inc. entered into a securities purchase agreement for a private placement financing (PIPE) to raise approximately $150 million in gross proceeds. In this PIPE, 9,197,887 shares of common stock were sold at a price of $11.38 per share. Additionally, 3,983,168 pre-funded warrants were sold at a purchase price of $11.3799 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.0001 per share of common stock. The PIPE is expected to close on August 14, 2026. The Securities Purchase Agreement for this private placement was dated August 13, 2026. MapLight Therapeutics, Inc. agreed to issue up to 13,181,055 shares of its Voting Common Stock and/or pre-funded warrants. The Common Stock of MapLight Therapeutics, Inc. is listed for trading on the Nasdaq Global Select Market under the symbol “MPLT”. #### Research and Development (R&D) Expenses For the second quarter of 2026, R&D expenses were $53.4 million, an increase from $26.8 million for the second quarter of 2025. This increase was primarily due to higher clinical trial expenses and employee-related expenses, including a $5.6 million increase in stock-based compensation. For the six months ended June 30, 2026, R&D expenses were $107.1 million, compared to $46.6 million for the same period in 2025. #### General and Administrative (G&A) Expenses G&A expenses for the second quarter of 2026 were $10.1 million, up from $3.8 million for the second quarter of 2025. This rise was mainly attributed to increased employee-related expenses, including a $2.9 million increase in stock-based compensation, and higher professional fees. For the six months ended June 30, 2026, G&A expenses were $20.9 million, compared to $7.6 million for the same period in 2025. #### Total Operating Expenses Total operating expenses for the six months ended June 30, 2026, were $128.1 million, compared to $54.2 million for the same period in 2025. #### Loss from Operations The loss from operations for the second quarter of 2026 was - $63.5 million, compared to - $30.7 million for the second quarter of 2025. For the six months ended June 30, 2026, the loss from operations was - $128.1 million, compared to - $54.2 million for the same period in 2025. #### Interest Income Interest income for the second quarter of 2026 was $2.3 million, up from $0.7 million for the second quarter of 2025. For the six months ended June 30, 2026, interest income was $4.8 million, compared to $1.5 million for the same period in 2025. #### Other Income, net Other income, net for the second quarter of 2026 was $1.0 million, compared to $0.1 million for the second quarter of 2025. For the six months ended June 30, 2026, other income, net was $2.4 million, compared to $0.5 million for the same period in 2025. #### Net Loss The net loss for the second quarter of 2026 was - $60.2 million, compared to - $29.8 million for the second quarter of 2025. For the six months ended June 30, 2026, the net loss was - $120.9 million, compared to - $52.2 million for the same period in 2025. #### Balance Sheet Data (as of June 30, 2026 vs. December 31, 2025) Total assets were $368.3 million as of June 30, 2026, down from $479.5 million as of December 31, 2025. Total current liabilities were $19.3 million as of June 30, 2026, up from $16.2 million as of December 31, 2025. Total liabilities were $20.0 million as of June 30, 2026, down from $21.1 million as of December 31, 2025. Total stockholders’ equity was $348.3 million as of June 30, 2026, down from $458.4 million as of December 31, 2025. #### Operational Metrics and Business Updates MapLight Therapeutics, Inc. reported positive results from the Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, which met its primary endpoint. Enrollment is ongoing in the Phase 2 VISTA trial for ML-007C-MA in Alzheimer’s Disease Psychosis (ADP), and ML-007C-MA received Fast Track designation from the FDA in December 2025 for ADP. The company plans to initiate ZEPHYR-2, a registrational study of ML-007C-MA in schizophrenia, and topline results for ML-007C-MA in ADP are expected in the second half of 2027. MapLight Therapeutics, Inc. will engage with the FDA at an End-of-Phase 2 meeting for ML-007C-MA in schizophrenia. The Phase 2 IRIS trial for ML-004 in autism spectrum disorder did not meet its primary endpoint, but a prespecified analysis showed clinically meaningful improvements in irritability in an adolescent subgroup. The company plans to engage with the FDA at an End-of-Phase 2 meeting following the autism spectrum disorder (ASD) irritability signal for ML-004, as data supports its potential development for irritability associated with ASD. MapLight Therapeutics, Inc. expects to complete IND-enabling studies for ML-009 in 2027, plans to nominate a preclinical candidate for ML-055 in 2026, and aims to finalize a preclinical candidate for ML-021 in 2027. The company is pausing further investment in preclinical and discovery-stage programs to focus resources on ML-007C-MA. #### Outlook / Guidance MapLight Therapeutics, Inc. expects its existing cash, cash equivalents, and investments, combined with the net proceeds from the PIPE, to be sufficient to fund the continued advancement of ML-007C-MA through 2028. This funding is anticipated to cover projected readouts for both the Phase 2 VISTA trial (expected in H2 2027) and the planned Phase 3 ZEPHYR-2 trial (expected in 2028). The company plans to engage with the FDA for End-of-Phase 2 meetings for both ML-007C-MA and ML-004 to discuss their respective registrational paths and future strategies. ### Related Stocks - [MPLT.US](https://longbridge.com/en/quote/MPLT.US.md) ## Related News & Research - [Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study](https://longbridge.com/en/news/296635926.md) - [Catalyst4 acquires $50.07 million of MapLight Therapeutics common shares](https://longbridge.com/en/news/296276892.md) - [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md) - [MapLight Q2 FY26 net loss widens to $60.19 million; R&D expenses rise to $53.44 million](https://longbridge.com/en/news/295839597.md) - [MapLight Therapeutics prices USD 150 million PIPE at USD 11.38 a share](https://longbridge.com/en/news/295804908.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**